Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers presented updated data at ESMO IO from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab-dlwr (Zynyz) in combination with platinum-based chemotherapy (carboplatin and paclitaxel) in adult patients with squamous cell carcinoma of the anal canal. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login